GGrantIndex
← Search

Protein Production / Monoclonal Antibody / Tissue Culture Shared Resource

$11,070P30FY2018CANIH

University Of Colorado Denver, Aurora CO

Investigators

Linked publications, trials & patents

Paper 39763739Paper 39737640Paper 39726772Paper 39711559Paper 39711135Paper 39684443Paper 39677775Paper 39677720Paper 39677022Paper 39671500Paper 39671496Paper 39630148Paper 39609428Paper 39604567Paper 39603869Paper 39574899Paper 39564580Paper 39554114Paper 39436696Paper 39400608Paper 39384405Paper 39342284Paper 39321266Paper 39311710Paper 39282307Paper 39266537Paper 39264810Paper 39215796Paper 39201277Paper 39191549Paper 39147413Paper 39139560Paper 39136655Paper 39120971Paper 39091762Trial NCT05073848Trial NCT05053737Trial NCT05006040Trial NCT04993859Trial NCT04988490Trial NCT04973007Trial NCT04963283Trial NCT04940468Trial NCT04925193Trial NCT04922112Trial NCT04916990Trial NCT04882111Trial NCT04866758Trial NCT04863092Trial NCT04634110Trial NCT04611022Trial NCT04565457Trial NCT04558138Trial NCT04544592Trial NCT04541407Trial NCT04535102Trial NCT04520867Trial NCT04486573Trial NCT04471363Trial NCT04408092Trial NCT04305366Trial NCT04300478Trial NCT04294693Trial NCT04208243Trial NCT04092803Trial NCT04091867Trial NCT04066218Trial NCT04042935Trial NCT04035408Trial NCT04028167Trial NCT04028063Trial NCT04001101Trial NCT03995082Trial NCT03976193Trial NCT03970226Trial NCT03958565Trial NCT03900793Trial NCT03891654Trial NCT03881098Trial NCT03781154Trial NCT03734653Trial NCT03617679Trial NCT03325634Trial NCT01886859Trial NCT01426334Trial NCT01232829Trial NCT00778167Patent 9434994Patent 8734778Patent 8715649Patent 8343502Patent 8337830Patent 8221763Patent 8153136Patent 8067559Patent 7910315Patent 7595060Patent 7563447Patent 7465454Patent 7083787

Abstract

PROTEIN PRODUCTION/ MONOCLONAL ANTIBODY/ TISSUE CULTURE SHARED RESOURCE (Core-544) ABSTRACT Overview: The Protein Production, Monoclonal Antibody, Tissue Culture Shared Resource (PMTSR) supports basic and translational research projects of the UCCC members by providing authenticated cell lines, producing monoclonal antibodies and recombinant proteins, and providing real time live cell imaging of cultured cells. Equipment: In 2015, we acquired an Essen BioScience IncuCyte, which offers real time imaging of living cells to quantitate cell proliferation, apoptosis, cell migration, chemotaxis and gene expression in an automated, high throughput manner. This instrument offers new technical advantages that were not previously available to our investigators. Services: The PMTSR has assembled a collection of over 200 authenticated human cancer cell lines, which are available to UCCC members at a reduced price relative to commercial services, to encourage the responsible use of established cell lines in biomedical research. Investigators can use the PMTSR to prepare large volumes (0.5 to 10 liters) of cells for in vitro and in vivo biological studies. For over 25 years, the PMTSR has produced hybridomas and purified monoclonal antibodies for use in basic and preclinical studies. Recombinant proteins are produced using baculovirus expression systems or in mammalian (293) cells. Consultation and Education: The PMTSR has advocated for the use of authenticated cell lines in cancer research by providing seminars outlining the impact of contaminated/misidentified cell lines upon biomedical research and by providing information on cell authentication services to UCCC members. A number of seminars have been offered regarding the use and technical abilities of the IncuCyte Bioimaging system. The PMTSR director and staff routinely consult with UCCC members on projects involving offered services and technologies. Management: The PMTSR is a UCCC SR managed by the UCCC and is overseen by the Associate Director for Basic Research. CCSG funding represents 31% of the annual operating budget. The remaining 69% support is from user fees. Use of Services: Since July 2011, 157 investigators have used the PMTSR services. Fifty- seven percent of users were UCCC members, representing all UCCC Programs and resulting in 65 peer- reviewed publications. Future Directions: 1) Expand our collection of authenticated cancer cell lines and continue to make them available to UCCC members at reduced prices as a means to ensure compliance with new NIH and journal policies. 2) Collaborate with Structural Biology Shared Resource (SBSR) to develop service offering on-demand purification of recombinant proteins. 3) Support the expanded use of the IncuCyte in cancer research. 4) Contribute to international efforts to develop platforms for murine cell line authentication and when available, provide these authenticated lines to UCCC members.

View original record on NIH RePORTER →